Clinical Research Directory
Browse clinical research sites, groups, and studies.
RSV Vaccine Response in Stem Cell and CAR-T Therapy Recipients
Sponsor: The Cooper Health System
Summary
This study evaluates whether the RSV vaccine Abrysvo can produce an antibody response in patients with blood cancers who have previously received a hematopoietic stem cell transplant (HSCT) or CAR-T cell therapy. The vaccine targets the prefusion F (preF) protein of RSV, which is an important component of protective immunity against the virus. The main goal of the study is to measure the change in antibody levels against the preF protein four weeks after vaccination compared with levels before vaccination. The study will also assess whether participants develop a meaningful immune response, defined as at least a four-fold increase in RSV neutralizing antibody levels four weeks after vaccination.
Official title: Seroconversion Following RSV Vaccination in Bone Marrow Transplant and CAR-T Patients
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2026-01-01
Completion Date
2027-06-30
Last Updated
2025-12-22
Healthy Volunteers
No
Interventions
Respiratory Syncytial Virus Prefusion F Vaccine (RSVpreF)
Patients will receive a single dose of the Respiratory Syncytial Virus Prefusion F Vaccine (RSVpreF) starting at three months post-HSCT or CAR-T therapy.
Locations (1)
Cooper University Hospital
Camden, New Jersey, United States